PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32991900-4	2020	Since the proteolytic cleavage of the S protein is critical for virus penetration into cells, a set of drugs, such as chloroquine, hydroxychloroquine, camostat mesylate have been tested in clinical trials to suppress this event.	Hydroxychloroquine	131-149	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	0-1	
33679150-5	2021	In this study, we docked five clinically used drug molecules, favipiravir, hydroxychloroquine, remdesivir, lopinavir, and ritonavir onto three target proteins, the receptor-binding domain of SARS-CoV-2 spike protein, SARS-CoV-2 main protease, and human furin protease.	Hydroxychloroquine	75-93	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	202-207	
32770567-7	2021	Moreover, out of three distinct binding sites (I, II and III) of spike core when HCQ binds only with site III (farthest from the nCoV-RBD of ACE2 contact), epigallocatechin gallate and theaflavin gallate bind all three sites.	Hydroxychloroquine	81-84	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	65-70	
33535144-5	2021	In this study, we focused on identifying a more potent analogue of HCQ and CQ against the spike protein of SAR-CoV-2 that can act as an effective antiviral agent for COVID-19 treatment.	Hydroxychloroquine	67-70	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	90-95	
33531790-12	2021	This finding was of particular importance that other compounds including hydroxychloroquine sulphate, lopinavir and ivermectin could bind with the spike protein only by weak Vander wall bonds and no hydrogen bond formation was noticed.	Hydroxychloroquine	73-100	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	147-152	
32770567-0	2021	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.	Hydroxychloroquine	126-144	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	74-79	
32920291-0	2020	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.	Hydroxychloroquine	16-34	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	86-91	
35000060-5	2022	Molecular docking of HCQ under physiological condition with spike protein, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp) of SARS-CoV2 showed - 8.52 kcal/mole binding score with RdRp, while the other two proteins showed relatively weaker binding affinity.	Hydroxychloroquine	21-24	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	60-65	
32562764-3	2020	Furthermore, it is emphasized that the viral spike protein is prevented from binding gangliosides, which are composed of a glycosphingolipid with one or more sialic acids, in the presence of chloroquine or hydroxychloroquine.	Hydroxychloroquine	206-224	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	45-50	
32696720-2	2021	In this paper, we demonstrate how hydroxychloroquine can act as a good inhibitor of SARS-CoV-2 Spike protein receptor-binding-domain using molecular docking studies.	Hydroxychloroquine	34-52	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	95-100	
32696720-3	2021	We also unveil how hydroxychloroquine can interfere in the prevention of Lys353 in hACE2 from interacting with the corresponding binding hotspot present on the Spike protein.	Hydroxychloroquine	19-37	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	160-165	
34396938-3	2021	Thus, the goal is to investigate the dynamic nature of HCQ derivatives against SARS-CoV-2 main protease and spike proteins.	Hydroxychloroquine	55-58	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	108-113	
34337036-8	2021	Then, by determining the activity of ACE2, we reveal that the interaction with the spike protein of SARS-CoV-2 leads to structural changes that at least partially displace the interaction of the said enzyme with HCQ.	Hydroxychloroquine	212-215	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	83-88